Causal Relationship between Adiponectin and Diabetic Retinopathy: A Mendelian Randomization Study in an Asian Population
- PMID: 33374471
- PMCID: PMC7823606
- DOI: 10.3390/genes12010017
Causal Relationship between Adiponectin and Diabetic Retinopathy: A Mendelian Randomization Study in an Asian Population
Abstract
Adiponectin (APN) is suggested to be a potential biomarker for predicting diabetic retinopathy (DR) risk, but the association between APN and DR has been inconsistent in observational studies. We used a Mendelian randomization (MR) analysis to evaluate if circulating APN levels result in DR. We applied three different genetic risk scores (GRS): GRSAll combined all 47 single nucleotide polymorphisms (SNPs), which from a genome-wide association study (GWAS) database-catalog reach significance level; GRSLimited comprised 16 GRSAll-SNPs with a rigorous threshold (p < 5.0 × 10-8 for GWAS), and GRSAPN combined 5 SNPs significantly associated with APN level. The MR-inverse-variance weighted method analysis showed that for each 1-SD increase in genetically induced increase in plasma APN, the OR of having DR was β = 0.20 (95% CI: -0.46-0.85, p = 0.553) for GRSAPN, 0.61 (95% CI: 0.10-1.13, p = 0.020) for GRSAll, and 0.57 (95% CI: -0.06 to 1.20, p = 0.078) for GRSLimited. Sensitivity analysis, including MR-egger regression and the weighted-median approach, did not provide evidence of the pleiotropic effect of IVs. Limited evidence for the causal role of APN in DR risk among Taiwanese diabetic patients was shown based on MR analysis in the present study.
Keywords: Mendelian randomization; adiponectin; causal relationship; diabetic retinopathy.
Conflict of interest statement
The authors have no conflict of interest to disclose.
Similar articles
-
Effect of adiponectin level and genetic variation of its receptors on diabetic retinopathy: A case-control study.Medicine (Baltimore). 2019 Mar;98(11):e14878. doi: 10.1097/MD.0000000000014878. Medicine (Baltimore). 2019. PMID: 30882695 Free PMC article.
-
Causal association between cystatin C and diabetic retinopathy: A two-sample Mendelian randomization study.J Diabetes Investig. 2024 Nov;15(11):1626-1636. doi: 10.1111/jdi.14273. Epub 2024 Aug 12. J Diabetes Investig. 2024. PMID: 39135422 Free PMC article.
-
Correlation between diabetic retinopathy and diabetic nephropathy: a two-sample Mendelian randomization study.Front Endocrinol (Lausanne). 2023 Nov 1;14:1265711. doi: 10.3389/fendo.2023.1265711. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027162 Free PMC article.
-
Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes.Diabetes. 2013 Oct;62(10):3589-98. doi: 10.2337/db13-0128. Epub 2013 Jul 8. Diabetes. 2013. PMID: 23835345 Free PMC article. Review.
-
Advances in molecular epidemiology of diabetic retinopathy: from genomics to gut microbiomics.Mol Biol Rep. 2025 Mar 13;52(1):304. doi: 10.1007/s11033-025-10383-9. Mol Biol Rep. 2025. PMID: 40080283 Review.
Cited by
-
Genome-Wide Associations and Confirmatory Meta-Analyses in Diabetic Retinopathy.Genes (Basel). 2023 Mar 5;14(3):653. doi: 10.3390/genes14030653. Genes (Basel). 2023. PMID: 36980925 Free PMC article.
-
Multiple polygenic risk scores can improve the prediction of systemic lupus erythematosus in Taiwan.Lupus Sci Med. 2024 May 9;11(1):e001035. doi: 10.1136/lupus-2023-001035. Lupus Sci Med. 2024. PMID: 38724181 Free PMC article.
-
The Association between ADIPOQ Gene Polymorphisms and Diabetic Retinopathy Risk: A Systematic Review and Meta-Analysis.Medicina (Kaunas). 2024 Aug 1;60(8):1254. doi: 10.3390/medicina60081254. Medicina (Kaunas). 2024. PMID: 39202535 Free PMC article.
-
Mendelian randomization analyses in ocular disease: a powerful approach to causal inference with human genetic data.J Transl Med. 2022 Dec 26;20(1):621. doi: 10.1186/s12967-022-03822-9. J Transl Med. 2022. PMID: 36572895 Free PMC article. Review.
-
The causal effect of hypertension, intraocular pressure, and diabetic retinopathy: a Mendelian randomization study.Front Endocrinol (Lausanne). 2024 Feb 6;15:1304512. doi: 10.3389/fendo.2024.1304512. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38379860 Free PMC article.
References
-
- Caldwell R.B., Bartoli M., Behzadian M.A., El-Remessy A.E., Al-Shabrawey M., Platt D.H., Caldwell R.W. Vascular endothelial growth factor and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Diabetes/Metab. Res. Rev. 2003;19:442–455. doi: 10.1002/dmrr.415. - DOI - PubMed
-
- Liu W.J., Lee L.T., Yen M.F., Tung T.H., Williams R., Duffy S.W., Chen T.H. Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: Implication for diabetic retinopathy screening in Taiwan. Diabet. Med. J. Br. Diabet. Assoc. 2003;20:727–733. doi: 10.1046/j.1464-5491.2003.01019.x. - DOI - PubMed
-
- Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., Pang Z., Chen A.S., Ruderman N.B., Chen H., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J. Biol. Chem. 2006;281:2654–2660. doi: 10.1074/jbc.M505311200. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous